See What HealthDay Can Do For You
Contact Us

Obesity Linked to Poor Outcome After Prostate Cancer

Biochemical and clinical failure rates increase with body mass index

MONDAY, June 26 (HealthDay News) -- Obese prostate cancer patients are more likely than non-obese patients to have biochemical failure or clinical recurrence of their disease after radiotherapy, according to a report published online June 26 in Cancer.

Sara S. Strom, Ph.D., from the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues conducted a retrospective analysis of 873 patients receiving external-beam radiotherapy for localized prostate cancer to determine if obesity influences treatment outcome.

The researchers found a statistically significant association between body mass index and both biochemical and clinical failure with a hazard ratio of 1.04 and 1.05, respectively. Outcomes tended to be worse with increasing body mass index.

"The current findings validate the important role of obesity, not only on biochemical failure but also on clinical recurrence, and suggest a link to the biologic basis of tumor progression that can be therapeutically exploited," the authors conclude.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.